New Antibiotic Class Is Aim Of Evotec R&D Pact With Nosopharm

 
• By Sten Stovall
  
Bacteria
Nosopharm's new Odilorhabdin class has a novel MoA inhibiting bacterial translation • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business